Aaaand it's out 🎉🎉🎉 This magazine feature profiles the participants of Novartis' BioCamp and Next Generation Scientist programs. I attended #BioCamp in 2015.
Before #GapSummit , there was BioCamp (any other alumni out there? lmao) BioCamp, or the International Biotechnology Leadership Camp, by @novartis was a three-day conference held at the Novartis Headquarters in Basel, Switzerland 🇨🇭 Every year, Novartis would give 60 top students from all over the world the opportunity to:
💊 Interact with real-life Novartis scientists and learn more about their approach to drug discovery
💊 Understand trends and challenges in the biotech and pharmaceutical sectors
💊 Connect with other students interested in drug discovery and the business behind it
💊 Work on a real-life #biotech business case
Though it's since been discontinued, I'll always remember BioCamp fondly since it was one of my first international conferences. It was my first time to encounter such a diverse cohort of people 🤯 During the networking breaks, I would feel quite overwhelmed and awkward, especially since I was a sheltered fresh grad at the time.
Members of my team, for instance, came from the Philippines 🇵🇭, Germany 🇩🇪, Vietnam 🇻🇳, Malaysia 🇲🇾, Morocco 🇲🇦 and the United Kingdom 🇬🇧 For the competition, we were tasked to create a business plan for an antibiotic that also had anti-cancer properties.
Unlike the other groups that decided to roll with the drug's antibiotic qualities, our group focused instead on promoting it as a novel anti-cancer drug (I even mocked up a fake Nature study saying it was effective in late-stage clinical trials!) Because we were the sole group to think outside the box, we won 🏆🏆🏆
Funnily enough, it's also because of BioCamp that I decided to pursue science communication. Before the conference, I was torn between taking up postgrad studies in bioenterprise or science communication. I found out during the conference that I preferred working on our pretend company's branding and pitch as opposed to crunching the financials sooooo, here I am now 🤪 Thanks for convincing me to go into science communication, BioCamp! ...
Hemodialysis is a therapy that can be necessary in the case of renal pathologies that lead to insufficient filtration. This kind of dialysis takes place thanks to a device which makes the blood to transit with appropriate velocities in porous tubes in which it gets in contact with special membranes that allows some substances to pass through them thanks to osmosis and to be taken away by a dialysis fluid.
Case study 1: Dynamics inside the arteriovenous fistula during dialysis
These plots represent the dynamics of blood inside the cephalic vein.
To this vein are attached two cannulae that lead blood to/from an external blood pump, which has a constant imposed flow of 400 mL/min. - Cephalic I refers to the initial part of the cephalic vein, between the brachial artery and the first needle - Cephalic II refers to the middle part of the vein, between the two needles
- Cephalic III refers to the final part of this vein, from the second needle to the brachial vein.
Blood flow in the cephalic vein between the 600 and the 1000 mL per minute means that the fistula is mature and useful as vascular access for hemodialysis.
As we can see from the plots, blood flow has a lower value in the central part of the vein since part of the flux is deviated outside the human body.
For more information, visit: www.computational-life.com and be in contact with us.